Neurogenic Inflammation in Diabetes

Inclusion Criteria: * Patients with type 2 diabetes with and without polyneuropathy. * Patients with type 2 diabetes with a history of Charcot's disease. * Healthy controls. * Signed informed consent. Exclusion Criteria: * Peripheral arterial disease: toe pressure \< 70 mm Hg and/or transcutaneous oxygen tension \< 40 mm Hg and/or claudication. * Renal insufficiency: MDRD creatinin clearance \< 30 ml/min. * Systemic disease such as vasculitis or rheumatoid arthritis. * Malignancy. * (Diabetic) foot ulcer. * Gout. * Bacterial infection of an extremity. * Skin condition of the dorsal aspect of the foot or the medial side of the upper arm. * Bleeding disorder such as hemophilia. * Use of medication for asthma. * Impaired immunity such as in HIV/AIDS. * Capillary blood glucose \< 3 mmol/l or \> 20 mmol/l at the time of the study. * Peripheral oedema. * Vaccination in the two months prior to study inclusion. * Chemotherapy or radiation therapy in the twelve months prior to study inclusion. * Surgery in the two months prior to study inclusion. * Previous adverse reaction to Candida albicans antigen. * Acute infection at the time of the study or in the month prior to study inclusion. * Transfusion in the two months prior to study inclusion. * Use of immunosuppressants in the two months prior to study inclusion. * Pregnancy or breastfeeding.